Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$298.9K-96.49%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacqueline E. Shea
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 112
- Beta
- 1.71
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -47.88
Financials
Revenue
$298.9K-96.5%Net Income
$-49.20MEBITDA
$-49.20MFree Cash Flow
$-15.27MEPS (diluted)
$-0.50Shares Outstanding (diluted)
98.63M+1498.1%Operating Expenses
$19.82MCash & Debt
$48.36MReturn of Capital
$0.00Revenue by Segment (annual)
$65.3KDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $65.3K | $-84.95M | $-1.81 |
| 2024 | $217.8K | $-107.25M | $-3.95 |
| 2023 | $832.0K | $-135.12M | $-6.09 |
| 2022 | $10.26M | $-279.82M | $-14.07 |
| 2021 | $1.77M | $-303.66M | $-1.42 |
| 2020 | $7.41M | $-166.41M | $-1.07 |
| 2019 | $4.11M | $-119.36M | $-0.97 |
| 2018 | $30.48M | $-96.97M | $-1.05 |
| 2017 | $42.22M | $-88.21M | $-1.08 |
| 2016 | $35.37M | $-73.74M | $-1.01 |
| 2015 | $40.57M | $-29.19M | $-0.43 |
| 2014 | $10.46M | $-36.12M | $-0.61 |
| 2013 | $13.47M | $-66.03M | $-1.43 |
| 2012 | $4.12M | $-19.67M | $-0.58 |
Valuation
INOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
53+6.67%Social Signal Score
Mentions (21)
- Newsmarketbeat.com·4d ago·Negative
Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval Inovio Pharmaceuticals NASDAQ: INO is preparing to launch its first approved product, VOCERYQ, after the U.S. Food and Drug Administration granted accelerated approval for the treatment of adults with recurrent respiratory papillomatosis, or RRP.
View source ↗ - Newsprnewswire.com·4d ago·Negative
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026 Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe PLYMOUTH MEETING, Pa., Nov. 18, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotechnolo…
View source ↗ - Newsprnewswire.com·11d ago·Neutral
INOVIO to Participate in Upcoming Investor Conferences PLYMOUTH MEETING, Pa., Nov. 11, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Jefferies G lobal Healthcare Conference in London Date: Wednesday, November 18 Time: 12:00 p.m.
View source ↗ - Newsprnewswire.com·12d ago·Negative
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP) VOCERYQ expected to be available to order and ship in approximately 60 days from the approval date with full commercial launch in first quarter 2027 VOCERYQ represents the first FD…
View source ↗ - Newsprnewswire.com·16d ago·Negative
INOVIO Announces Pricing of Approximately $75 Million Public Offering PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 58,747,235 shares of its common stock at a public offering price of $1.05 per share of common s…
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages Inovio Pharmaceuticals receives FDA Accelerated Approval for VOCERYQ [INO-3107] in recurrent respiratory papillomatosis, prompting a rating upgrade from "Hold" to "Buy." VOCERYQ is the first FDA-approved DNA medicine, highlighting the company's platform and potential for future DNA-based immunotherapy approvals and pipeline expansion. INO faces competition from Precigen's PAPZIMEOS but offers potential adva…
View source ↗ - Newsschaeffersresearch.com·19d ago·Neutral
4 Biotech Stocks Seeing Unusual Options Volume Today Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026 PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its third quarter 2026 financial results will be released after the market close on November 10, 2026.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
INOVIO to Participate in Upcoming Scientific Conferences PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences: Soft Bones Third International Scientific Meeting on Hypophosphatasia (New York) Presentation: Rare Disease Protein…
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript
View source ↗ - Newsbenzinga.com·20d ago·Neutral
Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) rose sharply in pre-market trading after the company disclosed that the FDA has granted accelerated approval for Voceryq for the treatment of adults with recurrent respiratory papillomatosis.
View source ↗ - Newsprnewswire.com·23d ago·Negative
INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make VOCERYQ available to order and ship in approximate…
View source ↗ - Newsprnewswire.com·33d ago·Neutral
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc.…
View source ↗ - Newsseekingalpha.com·72d ago·Neutral
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
View source ↗ - Newsmarketbeat.com·72d ago·Negative
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
View source ↗ - Newsmarketbeat.com·73d ago·Neutral
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·82d ago·Neutral
INOVIO to Participate in Upcoming Investor Conferences PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Cantor Global Healthcare Conference (New York) Date: Wednesday, September 9 Fireside Chat: 3:20 PM ET Webcast: https://…
View source ↗ - Newsmarketbeat.com·102d ago·Negative
Inovio Pharmaceuticals Q2 Earnings Call Highlights Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·102d ago·Negative
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the tr
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.15 per share
Typical surprise +20.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.50 vs $-0.21miss
- Wed, Aug 12$-0.07 vs $-0.22beat
- Wed, May 13$-0.28 vs $-0.35beat
- Thu, Mar 12$0.06 vs $-0.37beat
- Mon, Nov 10$-0.87 vs $-0.42miss
- Tue, Aug 12$-0.61 vs $-0.63beat
Estimates and results for INO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INO officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Nov 6, 2020 (59d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
